Trastuzumab in Combination With Metronomic Cyclophosphamide and Methotrexate in Patients With HER-2 Positive Metastatic Breast Cancer

BMC Cancer - United Kingdom
doi 10.1186/1471-2407-6-225
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Quality of Life in Patients With Metastatic Breast Cancer Treated With Metronomic Chemotherapy

Future Oncology
MedicineCancer ResearchOncology
2016English

Metronomic Chemotherapy in Metastatic Breast Cancer

Novel Research in Sciences
2019English

HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2004English

Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Pcn163 - Cost-Effectiveness of Add-On Pertuzumab Combined With Trastuzumab and Docetaxel Versus Placebo as Treatment of Her-2 Positive Metastatic Breast Cancer in Czech Republic

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Trastuzumab in Combination With AT-101 Induces Cytotoxicity and Apoptosis in Her2 Positive Breast Cancer Cells

Future Oncology
MedicineCancer ResearchOncology
2020English

Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib

AboutOpen
2018English

Serum HER-2 Concentration in Patients With Primary Breast Cancer

Journal of Clinical Pathology
MedicineForensic MedicinePathology
2006English

NT-proBNP Correlates With LVEF Decline in HER2-positive Breast Cancer Patients Treated With Trastuzumab

Cardio-Oncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy